Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 7/20 | 0.36 |
| ▸ | CTSL | P07711 | 6/20 | 0.36 |
| ▸ | CTSK | P43235 | 6/20 | 0.36 |
| ▸ | CTSS | P25774 | 5/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842049 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2GAARAB9AEPHX1KDM4E | |
| SCHEMBL12467348 | 0.89 | SMN1; SMN2 (0.37) | SMN1; SMN2GAARAB9AEPHX1KDM4E | |
| SCHEMBL8236530 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2GAARAB9AEPHX1KDM4E | |
| SCHEMBL11936283 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2GAARAB9AEPHX1KDM4E | |
| SCHEMBL16328219 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2GAARAB9AEPHX1KDM4E | |
| SCHEMBL13338252 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2GAARAB9AEPHX1KDM4E | |
| SCHEMBL11985580 | 0.83 | CTSB (0.38) | SMN1; SMN2GAARAB9AEPHX1KDM4E | |
| SCHEMBL11985586 | 0.83 | CTSB (0.38) | SMN1; SMN2GAARAB9AEPHX1KDM4E | |
| SCHEMBL15338725 | 0.82 | SMN1; SMN2 (0.37) | SMN1; SMN2GAARAB9AEPHX1KDM4E | |
| SCHEMBL12468295 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2GAARAB9AEPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143448-B2 | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives | VIROBAY, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090312571-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152474-A2 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | VIROBAY, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312571-A1 | PROCESS FOR THE PREPARATION OF (3S)-3-AMINO-N-CYCLOPROPYL-2-HYDROXYALKANAMIDE DERIVATIVES | HCN3, NPEPPS, HACL2 | SMN1; SMN2 3506/4885GAA 794/4885RAB9A 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.